Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.

Abstract

Richter syndrome (RS), an aggressive lymphoma occurring in the context of chronic lymphocytic leukaemia/small lymphocytic lymphoma, is associated with poor prognosis when treated with conventional immunochemotherapy, therefore, improved treatments are required. Immune checkpoint blockade has shown efficacy in some B-cell malignancies and modest responses in early clinical trials for RS. We investigated the immune checkpoint profile of RS as a basis to inform rational therapeutic investigations in RS. Formalin-fixed, paraffin-embedded biopsies of RS (n=19), de novo diffuse large B-cell lymphoma (DLBCL; n=58), transformed indolent lymphomas (follicular [tFL], n=16; marginal zone [tMZL], n=24) and non-transformed small lymphocytic lymphoma (SLL; n=15) underwent gene expression profiling using the NanoString Human Immunology panel. Copy number assessment was performed using next-generation sequencing. Immunohistochemistry (IHC) for LAG3 and PD-1 was performed. LAG3 gene expression was higher in RS compared to DLBCL (P=0·0002, log2FC 1·96), tFL (P<0·0001, log2FC 2·61), tMZL (P=0·0004, log2FC 1·79) and SLL (P=0·0057, log2FC 1·45). LAG3 gene expression correlated with the gene expression of human leukocyte antigen Class I and II, and related immune genes and immune checkpoints. IHC revealed LAG3 protein expression on both malignant RS cells and tumour-infiltrating lymphocytes. Our findings support the investigation of LAG3 inhibition to enhance anti-tumour responses in RS.